Literature DB >> 26136640

Reply to: N-terminal pro brain natriuretic peptide in coronary artery disease.

Hanan Radwan1, Abdelhakem Selem2, Kamel Ghazal3.   

Abstract

Entities:  

Year:  2015        PMID: 26136640      PMCID: PMC4481422          DOI: 10.1016/j.jsha.2015.04.002

Source DB:  PubMed          Journal:  J Saudi Heart Assoc        ISSN: 1016-7315


× No keyword cloud information.
In response to the letter by Professor Sim Sai Tin, we agree that the clinical usefulness of NT-proBNP has been widely discussed. Dr. Sim Sai Tin mentions the report by Ranjith et al. [1] on the usefulness of this biomarker in which the authors suggest that “NT-proBNP should be included in the risk assessment of ACS to provide guidance for further therapeutic strategies”. I would first like to state that the discussion of related subjects from various centers is mandatory and that multiple perspectives and the study of diverse demographics add to the enrichment of medical knowledge. Furthermore, our study was different to the one conducted by Ranjith et al. in several ways. First, our study populations were dissimilar. Our patients comprised those with unstable angina (48.48%; 64 patients) and NSTEMI (34.8%; 46 patients) while patients with STEMI represented only 16.6% (22 patients). On the other hand, most of the patients in the study by Ranjith et al. had STEMI (71%; 142 patients). Second, we performed serial assessments of NT-proBNP on admission and after cardiac catheterization; while Ranjith et al. assessed NT-proBNP only on admission. Third, coronary angiography was conducted on all patients in our study and we assessed the severity of coronary artery lesion, while Ranjith et al. conducted the same on only a small percentage (21% of his patients). And finally, most of our patients were treated by revascularization either by percutaneous coronary intervention (PCI) or surgical revascularization in addition to medical treatment, while the patients in the study by Ranjith et al. were treated medically in most cases, with cardiac catheterization performed on only 21% of their patients. Finally, our study concluded that NT-proBNP is not only a prognostic marker for complications and poor prognosis in acute coronary syndrome, but that it can also predict the severity of coronary artery stenosis and the number of vessels affected [2]. Written by Abdelhakem Selem Elsayed.
  2 in total

1.  Prognostic value of N-terminal-pro-brain natriuretic peptide measurements in patients with acute coronary syndromes.

Authors:  N Ranjith; R J Pegoraro; D P Naidoo; T M Esterhuizen
Journal:  Cardiovasc J S Afr       Date:  2006 Mar-Apr

2.  Value of N-terminal pro brain natriuretic peptide in predicting prognosis and severity of coronary artery disease in acute coronary syndrome.

Authors:  Hanan Radwan; Abdelhakem Selem; Kamel Ghazal
Journal:  J Saudi Heart Assoc       Date:  2014-05-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.